

Ruth R Wexler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/246059/publications.pdf>

Version: 2024-02-01

37
papers

1,422
citations

471509

17
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

1223
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5339-5356.	6.4	387
2	Discovery of 1-(3-(Aminobenzisoxazol-5-yl)-3-trifluoromethyl-N-[2-fluoro-4-((2-(dimethylaminomethyl)imidazol-1-yl)]phenyl)-1H-pyrazole-5-carboxamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1729-1744.	6.4	186
3	Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2-(methylsulfonyl)-[1,1-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa1. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 566-578.	6.4	175
4	Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 2. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 2760-2773.	6.4	81
5	Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 129-139.	1.6	78
6	Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 1. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 2752-2759.	6.4	57
7	Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 993-1000.	2.5	52
8	In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 416-423.	2.1	39
9	Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXR ² . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 372-377.	2.2	35
10	Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.. <i>Blood</i> , 2006, 108, 910-910.	1.4	32
11	N-in-1 Dosing Pharmacokinetics in Drug Discovery: Experience, Theoretical and Practical Considerations. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 2568-2580.	3.3	29
12	In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007351.	3.9	23
13	Discovery of Highly Potent Liver X Receptor ² Agonists. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 1207-1212.	2.8	21
14	Pyridine and pyridinone-based factor XIa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 925-930.	2.2	20
15	Identification of 1-{2-[4-chloro-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4-piperidine]-1-yl]phenyl}-3-[5-chloro-[1,3]thiazolo[5,4-d]imidazol-2-yl]pyridine-3-carboxamide (BMS-924659), a potent, efficacious and orally bioavailable P2Y1 antagonist as an antiplatelet agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1294-1298.	2.2	19
16	Selective Kur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3795-3803.	6.4	19
17	Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. <i>MedChemComm</i> , 2017, 8, 2093-2099.	3.4	19
18	In Vitro Evaluation of Apixaban, a Novel, Potent, Selective and Orally Bioavailable Factor Xa Inhibitor.. <i>Blood</i> , 2006, 108, 4130-4130.	1.4	18

#	ARTICLE	IF	CITATIONS
19	Potent Triazolopyridine Myeloperoxidase Inhibitors. ACS Medicinal Chemistry Letters, 2018, 9, 1175-1180.	2.8	16
20	Discovery of 5-Phenyl- <i>N</i> -(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent <i>K_{UR}</i> Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 831-834.	2.8	14
21	Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase. Bioorganic and Medicinal Chemistry, 2020, 28, 115723.	3.0	14
22	Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate. Journal of Medicinal Chemistry, 2021, 64, 3086-3099.	6.4	13
23	Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of <i>N</i> -[(1 <i>R</i>)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)pyridin-2-amine (BMS-795311). Journal of Medicinal Chemistry, 2015, 58, 9010-9026.	10.0	10
24	2-Amino-1,3,4-thiadiazoles in the 7-hydroxy- <i>N</i> -neopentyl spiropiperidine indoliny series as potent P2Y1 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2481-2485.	2.2	10
25	Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO). Bioorganic and Medicinal Chemistry Letters, 2021, 42, 128010.	2.2	9
26	Identification of 6-Hydroxypyrimidin-4(1 <i>H</i>)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists. ACS Medicinal Chemistry Letters, 2021, 12, 1766-1772.	2.8	8
27	Identification of 6-hydroxy-5-phenyl sulfonylpyrimidin-4(1 <i>H</i>)-one APJ receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2021, 50, 128325.	2.2	7
28	Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure. Journal of Medicinal Chemistry, 2021, 64, 18102-18113.	6.4	7
29	Design, synthesis and evaluation of phenethylaminoheterocycles as Kv1.5 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3018-3022.	2.2	6
30	Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 860-864.	2.2	5
31	Sulfonylated Benzothiazoles as Inhibitors of Endothelial Lipase. ACS Medicinal Chemistry Letters, 2018, 9, 1263-1268.	2.8	3
32	Benzothiazole-based compounds as potent endothelial lipase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126673.	2.2	3
33	Effects of the Factor Xa Inhibitor Apixaban on Venous Thrombosis and Hemostasis in Rabbits. Blood, 2006, 108, 917-917.	1.4	3
34	Discovery of hydroxyl 1,2-diphenylethanamine analogs as potent cholesterol ester transfer protein inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3278-3281.	2.2	2
35	From basic science to life-saving therapy: the rationale, and drug discovery efforts that led to the direct factor Xa inhibitor eliquis. Journal of Thrombosis and Thrombolysis, 2021, 52, 403-407.	2.1	1
36	Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor. ACS Medicinal Chemistry Letters, 2019, 10, 911-916.	2.8	0

#	ARTICLE	IF	CITATIONS
37	Design and preparation of N-linked hydroxypyridine-based APJ agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 73, 128882.	2.2	0